Vyant Bio (VYNT) Misses Q2 EPS by 14c

Vyant Bio (NASDAQ: VYNT) reported Q2 EPS of ($0.14), $0.14 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $1.9 million versus the consensus estimate of $10.77 million.

For earnings history and earnings-related data on Vyant Bio (VYNT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79